Abstract: The present invention relates to a method for the hydrocyanation of organic ethylenically unsaturated compounds including at least one nitrile function. The invention specifically relates to a method for the hydrocyanation of a hydrocarbon compound including at least one ethylenic unsaturation by a reaction with hydrogen cyanide in a liquid medium and in the presence of a catalyst including a metal element selected from the transition metals and an organophosphorous ligand, the organophosphorous ligand including a compound of general formula (I), where R1 and R2, which are identical or different, are a linear or branched alkyl radical having 1-12 carbon atoms, which can include heteroatoms, or an optionally substituted aromatic or cycloaliphatic radical that can include heteroatoms, wherein the covalent bond between P and R1, and that between P and R2, are P—C bonds.

Abstract: Iridium compounds and their uses are disclosed herein. For example, carbazole containing iridium compounds are disclosed. The compounds are useful in many devices, including, but not limited to, electroluminescent devices.

Abstract: A highly energetic, high-oxygen carrier suitable as high-performing green replacement for ammonium perchlorate includes halogen-free ionic salts consisting of fuel cations and over-oxidized anions containing multiple nitro- or nitromethyl-substituted azolyl ligands. The over-oxidized anions include a central atom selected from the group consisting of boron, aluminum, or gallium. Characteristically, the carrier has sufficient amounts of oxygen for complete or near complete combustion of the over-oxidized anions, the fuel cations, metal additives and binders.

Abstract: A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting a solution of an organic azide and a terminal alkyne with a source of catalytic Cu(I) ion to form a 1,4-disubstituted 1,2,3-triazole, wherein the source of Cu(I) ion comprises Cu(II) and a metal capable of reducing Cu(II) to Cu(I). In some embodiments, the metal capable of reducing Cu(II) to Cu(I) is selected from the group consisting of Al, Be, Co, Cr, Fe, Mg, Mn, Ni, and Zn.

Abstract: The present invention relates to the field of pharmaceutical chemistry, specifically relates to a statin intermediate having formula I and preparation thereof. The advantages of the method used to prepare the chiral sulfone intermediate having formula I are that a fluorophore is introduced at the beginning of the synthesis, and the intermediates are mostly solid, which enables quality control to be easily carried out.

Abstract: A process for preparation of catalysts for the production of acrylonitrile, acetonitrile and hydrogen cyanide comprising contacting at an elevated temperature, propylene, ammonia and oxygen in the vapor phase in the presence of a catalyst, said catalyst comprising a complex of metal oxides wherein a heat-decomposable nitrogen containing compound is added during the process for the preparation of the catalyst.

Abstract: Provided is a novel iridium catalyst complex which is useful in the dehydrogenation of alkanes. The iridium complex comprises the metal iridium atom complexed with a benzimidazolyl-containing ligand. The iridium atom can be coordinated with the nitrogen atoms in the benzimidazolyl-containing ligand to form an NCN pincer ligand complex. In another embodiment, the iridium catalyst is used, with or without a co-catalyst, in a dehydrogenation reaction converting alkanes to olefins. The reaction can be in a closed or open system, and can be run in a liquid or gaseous phase.

Abstract: The present invention relates to a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R represents one or more groups independently selected from fluorine, chlorine, bromine, and iodine, said process comprising the cyclopropanation of a compound of formula (II) with ethylene carbonate or ethylene sulfate: wherein X is chlorine, bromine, iodine or a triflate group (CF3SO3) or a group wherein R is as defined above and G is —CN or —COOR2 wherein R2 is a C1-C4 straight or branched alkyl chain.

Abstract: The present invention provides a novel light-emitting material, which is a blue fluorescent material performs a high quantum yield of ˜86%, and can be doped into a host light-emitting layer of an organic light emitting diode (OLED) for being a guest light-emitting material, so as to increase the external quantum efficiency, the power efficiency and the current efficiency of the OLED. Most importantly, a variety of experiment results have proved that the OLED having the novel light-emitting material can emit a deep blue light with CIE coordinates of (0.156, 0.055). Moreover, the experiment results also proved that the novel light-emitting material can be applied in fabricating OLED through dry process and/or wet process; so that, the novel light-emitting material is helpful to the low-cost mass production of OLEDs.

Abstract: The invention relates to the field of medicine, and specifically to preparations for treating skin lesions, in particular viral, benign, precancerous and cancerous, non-metastasizing, dysplastic and inflammatory lesions of the visible mucous membranes, and also viral and fungal skin and nail lesions, and for correcting wrinkles and senile pigment blemishes, said preparations comprising solutions of complex compounds of salts of zinc and alpha-chlorocarboxylic acids of general formula [Zn(RCH2?xClxCOOH)n(H2O)4?n]+2.2[RCH2?xClxCOO]?, where R=alkyl, H or Cl, x=1-2 and n=0-4, in a corresponding alpha-chlorocarboxylic acid, wherein the content of zinc in the solution is 0.25-10.0% and the content of acid is 10-90%. The preparation may additionally contain an additive perfume, for example an ethyl ester of the corresponding alpha-chlorocarboxylic acid. The treatment method consists in that 2-5 doses of the preparation, which has been precooled to 10-15° C.

Abstract: The invention relates to a method for preparation of ruthenium-based carbene catalysts with chelating alkylidene ligands (so-called “Hoveyda-type catalysts”) in a cross metathesis reaction by reacting a ruthenium-alkylidene complex with an olefin derivate in the presence of a polymer-supported cation-exchange resin (PSR) acting as a ligand (i.e. phosphine or amine) scavenger. Preferably, penta-coordinated ruthenium benzylidene or indenylidene carbene complexes are employed. The polymer-supported cation-exchange resin (PSR) may be an acidic resin (comprising sulfonic acid or carboxylic groups) or a resin containing carboxylic acid chloride (—COCl) groups or sulfonyl chloride (—SO2Cl) groups. The process is versatile and environmentally friendly; high yields are obtained.

Abstract: Described are methods for preparing copper(I) 5-nitrotetrazolate, which include reacting copper(II) sulfate pentahydrate, sodium nitrite, 5-aminotetrazole, and at least one of nitric acid and urea in water.

Abstract: N-heterocyclic (“NHC”) carbenes and NHC carbene-metal complexes. The NHC carbene having a formula: wherein R1 is an aromatic or aliphatic group, and R2 is an aromatic or aliphatic group, R3 is a fluorinated alkyl chain, R4 is a fluorinated alkyl chain or a proton. NHC carbene-metal complexes having the formula: wherein M is a metal, and each of L1, L2, and L3 ligands is a backfluorinated NHC carbene.

Abstract: Copper(I) complexes for the emission of light with a structure according to formula A: wherein: M is Cu(I); L-B-L: a neutral, bidentate ligand, Z4-Z7: includes N or the fragment CR, with R=organic group, selected from the group consisting of: hydrogen, halogen or deuterium or groups which are bound via oxygen (—OR??), nitrogen (—NR??2), or phosphorous atoms (PR??2) as well as alkyl, aryl, heteroaryl, alkenyl, alkinyl, trialkylsilyl and triarylsilyl groups or substituted alkyl, aryl, heteroaryl and alkenyl groups with substituents such as halogens or deuterium or lower alkyl groups; X is either CR??2 or NR??; Y is either O, S or NR??; Z8 includes the fragment CR?, with R?=O*R??, N*R??2 or P*R??2, wherein the bond to the Cu atom is carried out via these groups; R? is a sterically demanding substituent, which inhibits a change in geometry in direction to planarization of the complex in excited state, R??=organic group which is selected from the group consisting of: hydrogen, halogen or deuterium, as well

Abstract: The disclosure is directed to: (a) phosphacycle ligands; (b) methods of using such phosphacycle ligands in bond forming reactions; and (c) methods of preparing phosphacycle ligands.

Abstract: A method comprising: (a) enzymatically processing an O-acetylhomoserine (OAHS) fermentation liquor to produce L-methionine and an acetate source; (b) separating at least a portion of said L-methionine from at least a fraction of said acetate source to form separated L-methionine and a residual liquor comprising an acetate-source; and (c) recovering at least a portion of said acetate source from said residual liquor as recovered acetate.

Abstract: This invention relates generally to olefin metathesis, and more particularly relates to the synthesis of terminal alkenes from internal alkenes using a cross-metathesis reaction catalyzed by a selected olefin metathesis catalyst. In one embodiment of the invention, for example, a method is provided for synthesizing a terminal olefin, the method comprising contacting an olefinic substrate comprised of at least one internal olefin with ethylene, in the presence of a metathesis catalyst, wherein the catalyst is present in an amount that is less than about 1000 ppm relative to the olefinic substrate, and wherein the metathesis catalyst has the structure of formula (II) wherein the various substituents are as defined herein. The invention has utility, for example, in the fields of catalysis, organic synthesis, and industrial chemistry.

Abstract: A pharmaceutically acceptable salt, prodrug or derivative compound of the formula I, wherein R1 is selected from H, a (C1-C5) alkyl group and a COR4 group; R2 is selected from H, a (C1-C5) alkyl group and a COR5 group; R3 is selected from H, a (C1-C5) alkyl group, a (C1-C5)-O-alkyl group, a cycloalkyl of (C5-C6) carbon atoms, an aryl group, and an aryl (C1-C5) alkyl group wherein the aryl group can be an unsubstituted aryl or substituted with one or more R6 groups and an NHCOR5 group, or the R2 and R3 groups together with N may form a piperidine, morpholine or piperazine group; R4 is selected from H and a (C1-C5)alkyl group; R5 is selected from an aryl group unsubstituted or substituted with one or more R6, linear or branched(C1-C5) alkyl or pyridyne groups and a pyridine group; R6 is selected from (C1-C5)alkyl groups, halogen and nitro.

Abstract: The present invention relates to a novel dicarboximide derivative of berbamine represented by formula I, including, but not limited to, a phthalimide derivative of berbamine and an aromatic heterocyclic dicarboximide derivative of berbamine, or a pharmaceutically acceptable salt thereof, to a process for preparation of the same, to a pharmaceutical composition comprising said compound and to use thereof in manufacture of an antitumor medicament.

Abstract: This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.